Drug Therapy for Rheumatoid Arthritis in Adults
Summary of Benefits: DMARDs in the Treatment of Patients With Early Rheumatoid Arthritis (2 of 2)
Biologic disease-modifying anti-rheumatic drugs (DMARDs) more effectively limit radiographic evidence of progression than do oral DMARDs.
For methotrexate (MTX)-naïve patients with aggressive early rheumatoid arthritis, combining MTX with a biologic DMARD (abatacept, adalimumab, etanercept, or infliximab) provides greater improvement than biologic DMARD monotherapy for symptom response, clinical remission rates, and radiographic progression.
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic DMARD | withdrawal | adverse events | adverse effects | radiographic evidence | radiographic progression | early RA | aggressive RA | methotrexate | abatacept | adalimumab | etanercept | infliximab | remission | symptom response
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.